March 7th, 2022
Wyss Institute’s eRapid sensor technology licensed to Antisoma Therapeutics
Low-cost, multiplexed, electrochemical biomarker detection platform will be commercialized in point-of-care diagnostics
News
Press Contact: Kirsten Mabry | (617) 495-4157
Featured Tags:
February 23rd, 2022
Cantex licenses IP from Harvard to develop repurposed drug identified by Wyss Institute to treat inflammatory lung diseases including COVID-19
Organ Chip studies revealed azeliragon can reduce virus-associated inflammation in human lung tissue
February 22nd, 2022
Harvard licenses kidney engineering technology to Trestle Biotherapeutics to facilitate new kidney replacement therapies
Powerful combination of 3D bioprinting and stem cell-based tissue engineering could enable new approaches to treating chronic kidney disease
February 16th, 2022
Startup internships ‘reward curiosity’
Summer program with Matrix Partners places CS students at new ventures
February 10th, 2022
Alkem licenses technology from Harvard University, aiming to treat ischemic injury and vascular diseases
Novel delivery of established growth and neurotropic factors enables local, sustained release for greater efficacy
